Showing results (1841-1850 of 1,859) with videos related to

Sort By:
Pageof 186
Cell Research|September 29, 2004
The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cellsXiao Dong Wu, Bo Shang, Rui Fu Yang, et al.
Ebiomedicine|February 10, 2018
Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass SurgeryQing-Run Li, Zi-Ming Wang, Nicolai J Wewer Albrechtsen, et al.
Trends in Molecular Medicine|October 6, 2023
Human genetics and molecular genomics of Chiari malformation type 1Kedous Y Mekbib, William Muñoz, Garrett Allington, et al.
Gastroenterology|December 27, 2022
Integrated Multi-Omics Landscape of Liver MetastasesShuai Yang, Ling Qian, Zhixuan Li, et al.
JAMA Network Open|May 8, 2026
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical TrialJian Zhu, Cheng Zhao, Cundong Mi, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases|November 27, 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 13, 2025
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III TrialXu Liu, Liling Xu, Cheng Zhao, et al.
Chinese Journal of Traumatology = Zhonghua Chuang Shang Za Zhi|March 10, 2019
Chinese Trauma Surgeon Association for management guidelines of vacuum sealing drainage application in abdominal surgeries-Update and systematic reviewYang Li, Pei-Yuan Li, Shi-Jing Sun, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 26, 2007
[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma]Xiao-dong Huang, Jun-lin Yi, Li Gao, et al.
Pageof 186